Biochemistry, Genetics and Molecular Biology
Cytogenetics
100%
Myeloid
75%
Genomics
72%
Fluorescence in Situ Hybridization
66%
Karyotype
56%
Array Comparative Genomic Hybridization
51%
B Cell
51%
Overall Survival
49%
Gene Mutation
28%
Genetics
27%
Chromothripsis
27%
Comparative Genomic Hybridization
25%
Chromosomal Aberration
24%
Microarrays
24%
Next Generation Sequencing
23%
Morphology
23%
Loss of Heterozygosity
21%
Spectral Karyotyping
19%
Fibroblast Growth Factor Receptor 1
18%
ETV6
17%
Single-Nucleotide Polymorphism
17%
Genome Instability
16%
Epigenetics
14%
Amplicon
14%
Molecular Inversion Probe
13%
Chromosomal Rearrangement
13%
DNA Microarray
13%
P21
12%
Chromosomal Abnormalities
12%
Gene Dosage
12%
Oncogene
12%
Philadelphia Chromosome
12%
MDS1 and EVI1 Complex Locus Protein
12%
Karyotyping
11%
T Cell
10%
Chromosome 21
10%
Stem Cell
10%
Plasmacytoid Dendritic Cell
10%
ROS1
10%
Hematopoietic Stem Cell Transplantation
10%
Cytokine Receptor
10%
Cancer Stem Cell
10%
Enhancer Region
10%
Allogeneic Stem Cell Transplantation
10%
Chromosome 8
10%
G Banding
9%
KRAS
9%
Mouse Model
8%
Copy-Number Variation
8%
High Risk Population
8%
Keyphrases
Acute Myeloid Leukemia
56%
Fluorescence in Situ Hybridization
50%
Overall Survival
45%
Myeloid Neoplasms
41%
Tumor
36%
Array Comparative Genomic Hybridization (aCGH)
33%
Single Institution
32%
Myelodysplastic Syndrome
32%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
31%
Complex Karyotype
30%
TP53 mutation
27%
Chromothripsis
25%
Genetic Modification
25%
Pediatric
24%
Chromosomal Microarray
24%
Overexpression
23%
Follicular Lymphoma
21%
Histological Analysis
21%
Osteosarcoma
20%
Spectral Karyotyping
20%
Comparative Genomic Hybridization
19%
Adult Patients
19%
Chromosomal Aberrations
19%
Copy number Variation
18%
Loss of Heterozygosity
18%
Copy number Aberrations
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Chemotherapy
17%
Myeloproliferative Neoplasms
16%
Molecular Cytogenetics
16%
Genetic Aberrations
16%
Next-generation Sequencing
16%
Leukemia Patients
16%
Bone Marrow
16%
Mantle Cell Lymphoma
16%
Uterine Leiomyosarcoma
16%
Poor Prognosis
16%
MECOM Rearrangement
16%
Diffuse Large B-cell Lymphoma (DLBCL)
16%
Leiomyoma with Bizarre nuclei
15%
Double Hit
15%
Pediatric Patients
15%
Morphological Characteristics
15%
Aberrations
15%
Genomic Instability
14%
Prognostic Significance
14%
Inv(3)(q21q26.2)
14%
Cytogenetic Abnormalities
14%
Leiomyosarcoma
14%
Chromosomal Amplification
14%
Medicine and Dentistry
Neoplasm
89%
Acute Myeloid Leukemia
53%
Overall Survival
40%
Karyotype
40%
Pediatrics
36%
Myelodysplastic Syndrome
35%
Fluorescence in Situ Hybridization
29%
Angioleiomyoma
27%
Diseases
25%
Chemotherapy
24%
Chromosome Aberration
23%
Follicular Lymphoma
20%
Gene Mutation
20%
Morphology
19%
Ganglioglioma
16%
Acute Lymphoblastic Leukemia
16%
Leiomyosarcoma
16%
B Cell
15%
Myeloproliferative Neoplasm
15%
Diffuse Large B-Cell Lymphoma
14%
Malignant Neoplasm
14%
Acute B-Cell Lymphoblastic Leukemia
13%
Hematopoietic Stem Cell Transplantation
13%
Myeloma
12%
Chronic Myelomonocytic Leukemia
12%
Mantle Cell Lymphoma
10%
MDS1 and EVI1 Complex Locus Protein
10%
Lung Adenocarcinoma
10%
Prolymphocytic Leukemia
10%
Allogeneic Stem Cell Transplantation
10%
Chromosome 21
10%
Fibroblast Growth Factor Receptor 1
10%
Hazard Ratio
10%
Chromothripsis
10%
Next Generation Sequencing
10%
Lung Cancer
10%
Lymphoid Leukemia
10%
Tumor Cell
9%
B-Cell Lymphoma
9%
Diagnosis
9%
Stem Cell Transplant
9%
Risk Stratification
9%
P16
9%
ASXL1
8%
Array Comparative Genomic Hybridization
8%
Clinical Significance
8%
Precursor
7%
Cancer Stem Cell
7%
Prothrombin
7%
Cytokine Receptor
7%